Literature DB >> 23378539

A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe.

P Bertuccio1, C Bosetti, F Levi, A Decarli, E Negri, C La Vecchia.   

Abstract

BACKGROUND: To update and compare mortality from primary liver cancer (PLC) and intrahepatic cholangiocarcinoma (ICC) in Europe in 1990-2010.
MATERIALS AND METHODS: We used data from the World Health Organization (WHO) to compute age-standardized (world population) mortality rates, and used joinpoint analysis to identify substantial changes.
RESULTS: Between 2002 and 2007, PLC rates in the European Union (EU) declined from 3.9 to 3.6/100,000 men. Around 2007, the highest male rates were in France (6.2/100,000), Spain (4.9), and Italy (4.0), while the lowest ones were in Sweden (1.1), the Netherlands (1.2), and the UK (1.8). In women, mortality was lower (0.8/100,000 in 2007 in the EU), and showed more favourable trends, with a decline of over 2% per year over the last two decades as compared with 0.4% in men, in the EU. In contrast, the EU mortality from ICC increased by around 9% in both sexes from 1990 to 2008, reaching rates of 1.1/100,000 men and 0.75/100,000 women. The highest rates were in UK, Germany, and France (1.2-1.5/100,000 men, 0.8-1.1/100,000 women).
CONCLUSIONS: PLC mortality has become more uniform across Europe over recent years, with an overall decline; in contrast, ICC mortality has substantially increased in most Europe.

Entities:  

Keywords:  cancer; cholangiocarcinoma, hepatocellular carcinoma; intrahepatic; liver; mortality

Mesh:

Year:  2013        PMID: 23378539     DOI: 10.1093/annonc/mds652

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  42 in total

Review 1.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 2.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

3.  Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.

Authors:  Jie-Hui Tan; Wan-Yan Zhou; Lei Zhou; Rong-Chang Cao; Guo-Wei Zhang
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

Review 4.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

5.  The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation.

Authors:  Safak Gül-Klein; Paulina Schmitz; Wenzel Schöning; Robert Öllinger; Georg Lurje; Sven Jonas; Deniz Uluk; Uwe Pelzer; Frank Tacke; Moritz Schmelzle; Johann Pratschke; Ramin Raul Ossami Saidy; Dennis Eurich
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

6.  Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification.

Authors:  Gia L Tyson; Jawad A Ilyas; Zhigang Duan; Linda K Green; Mamoun Younes; Hashem B El-Serag; Jessica A Davila
Journal:  Dig Dis Sci       Date:  2014-09-10       Impact factor: 3.199

Review 7.  Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: an intricate pathway.

Authors:  Romilda Cardin; Marika Piciocchi; Marina Bortolami; Andromachi Kotsafti; Luisa Barzon; Enrico Lavezzo; Alessandro Sinigaglia; Kryssia Isabel Rodriguez-Castro; Massimo Rugge; Fabio Farinati
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 8.  Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?

Authors:  Edoardo G Giannini; Alessandro Cucchetti; Virginia Erroi; Francesca Garuti; Federica Odaldi; Franco Trevisani
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

9.  Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Authors:  Yu Wang; Xiwei Ding; Shaoqing Wang; Catherine D Moser; Hassan M Shaleh; Essa A Mohamed; Roongruedee Chaiteerakij; Loretta K Allotey; Gang Chen; Katsuyuki Miyabe; Melissa S McNulty; Albert Ndzengue; Emily G Barr Fritcher; Ryan A Knudson; Patricia T Greipp; Karl J Clark; Michael S Torbenson; Benjamin R Kipp; Jie Zhou; Michael T Barrett; Michael P Gustafson; Steven R Alberts; Mitesh J Borad; Lewis R Roberts
Journal:  Cancer Lett       Date:  2016-05-20       Impact factor: 8.679

10.  Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012.

Authors:  Manuel Coelho da Rocha; Rui T Marinho; Teresa Rodrigues
Journal:  GE Port J Gastroenterol       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.